[go: up one dir, main page]

NO962346D0 - Humaniserte antistoffer og anvendelser derav - Google Patents

Humaniserte antistoffer og anvendelser derav

Info

Publication number
NO962346D0
NO962346D0 NO962346A NO962346A NO962346D0 NO 962346 D0 NO962346 D0 NO 962346D0 NO 962346 A NO962346 A NO 962346A NO 962346 A NO962346 A NO 962346A NO 962346 D0 NO962346 D0 NO 962346D0
Authority
NO
Norway
Prior art keywords
humanized antibodies
humanized
antibodies
Prior art date
Application number
NO962346A
Other languages
English (en)
Other versions
NO962346L (no
Inventor
Yee-Tharn Augustine Lin
Original Assignee
T Cell Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by T Cell Sciences Inc filed Critical T Cell Sciences Inc
Publication of NO962346D0 publication Critical patent/NO962346D0/no
Publication of NO962346L publication Critical patent/NO962346L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO962346A 1993-12-08 1996-06-05 Humaniserte antistoffer og anvendelser derav NO962346L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB939325182A GB9325182D0 (en) 1993-12-08 1993-12-08 Humanized antibodies or binding proteins thereof specific for t cell subpopulations exhibiting select beta chain variable regions
PCT/IB1994/000387 WO1995016038A2 (en) 1993-12-08 1994-11-21 Humanized antibodies and uses thereof

Publications (2)

Publication Number Publication Date
NO962346D0 true NO962346D0 (no) 1996-06-05
NO962346L NO962346L (no) 1996-08-06

Family

ID=10746330

Family Applications (1)

Application Number Title Priority Date Filing Date
NO962346A NO962346L (no) 1993-12-08 1996-06-05 Humaniserte antistoffer og anvendelser derav

Country Status (24)

Country Link
US (1) US5861155A (no)
EP (1) EP0737250A1 (no)
JP (1) JPH09509307A (no)
KR (2) KR100239607B1 (no)
CN (1) CN1063792C (no)
AU (1) AU699249B2 (no)
BR (1) BR9408278A (no)
CA (1) CA2178622A1 (no)
CZ (2) CZ287347B6 (no)
EE (1) EE03271B1 (no)
FI (1) FI962377A7 (no)
GB (1) GB9325182D0 (no)
HU (1) HUT75553A (no)
IL (1) IL111926A (no)
LV (1) LV11631B (no)
NO (1) NO962346L (no)
NZ (1) NZ276170A (no)
PL (1) PL180157B1 (no)
RU (1) RU2139934C1 (no)
SG (1) SG48420A1 (no)
SK (1) SK73596A3 (no)
UA (1) UA29494C2 (no)
WO (1) WO1995016038A2 (no)
ZA (1) ZA949341B (no)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6348581B1 (en) * 1996-10-31 2002-02-19 The Dow Chemical Company High affinity humanized anti-TAG-72 monoclonalantibodies
CN1064052C (zh) * 1997-09-29 2001-04-04 中国科学院微生物研究所 甲状旁腺素相关蛋白人源化抗体及其制备方法
AU2444899A (en) * 1998-01-22 1999-08-09 Astrazeneca Ab Pharmaceutical formulation comprising an antibody and a citrate buffer
GB9906233D0 (en) * 1999-03-19 1999-05-12 Univ Newcastle Bone formation
AU2002213398A1 (en) * 2000-10-20 2002-05-06 Whitehead Institute For Biomedical Research Expression vectors and uses thereof
US20060233790A1 (en) * 2002-03-22 2006-10-19 Shiroh Futaki Immunoglobulin/hydrophilic peptide complexes
US7794716B2 (en) 2002-07-25 2010-09-14 Glenveigh Pharmaceuticals, Llc Antibody composition and passive immunization against pregnancy-induced hypertension
GB0302740D0 (en) * 2003-02-06 2003-03-12 Axis Shield Asa Assay
US7794713B2 (en) 2004-04-07 2010-09-14 Lpath, Inc. Compositions and methods for the treatment and prevention of hyperproliferative diseases
PT1742966E (pt) * 2004-04-22 2014-02-05 Agensys Inc Anticorpos e moléculas derivadas daí que se ligam às proteínas steap-1
WO2006137354A1 (ja) * 2005-06-21 2006-12-28 Medical & Biological Laboratories Co., Ltd. アミロイド線維形成に対する阻害活性を有する抗体
KR100740201B1 (ko) * 2005-10-21 2007-07-18 삼성전자주식회사 듀얼 전송 스트림 생성 장치 및 그 방법
US20090074720A1 (en) * 2005-10-28 2009-03-19 Sabbadini Roger A Methods for decreasing immune response and treating immune conditions
US20080213274A1 (en) * 2005-10-28 2008-09-04 Sabbadini Roger A Compositions and methods for the treatment and prevention of fibrotic, inflammatory, and neovascularization conditions of the eye
WO2007125089A2 (en) * 2006-04-28 2007-11-08 ETH Zürich Antibodies for the detection of bacillus anthracis and vaccine against b. anthracis infections
US7862812B2 (en) * 2006-05-31 2011-01-04 Lpath, Inc. Methods for decreasing immune response and treating immune conditions
CA2656347A1 (en) 2006-07-03 2008-01-10 Charles David Adair Composition for modulating the expression of cell adhesion molecules
AU2007313822A1 (en) 2006-10-27 2008-05-08 Lpath, Inc. Compositions and methods for treating ocular diseases and conditions
DK2087002T3 (da) 2006-10-27 2014-10-27 Lpath Inc Sammensætninger og fremgangsmåder til binding af sphingosin-1-phosphat
ES2585702T3 (es) 2007-05-30 2016-10-07 Lpath, Inc Composiciones y métodos para la unión al ácido lisofosfatídico
US9163091B2 (en) * 2007-05-30 2015-10-20 Lpath, Inc. Compositions and methods for binding lysophosphatidic acid
US20110064744A1 (en) * 2007-05-30 2011-03-17 Sabbadini Roger A Prevention and treatment of pain using antibodies to lysophosphatidic acid
CA2695981A1 (en) 2007-08-10 2009-02-19 Agency For Science, Technology And Research (A*Star) Vhz for diagnosis and treatment of cancer
EP2201040A1 (en) * 2007-09-24 2010-06-30 Vanderbilt University Monoclonal antibodies to respiratory syncytial virus and uses thereof
US8361465B2 (en) * 2007-10-26 2013-01-29 Lpath, Inc. Use of anti-sphingosine-1-phosphate antibodies in combination with chemotherapeutic agents
EP2331107A4 (en) * 2008-08-08 2011-08-24 Agency Science Tech & Res VHZ FOR DIAGNOSIS AND TREATMENT OF TUMORS
US8871202B2 (en) 2008-10-24 2014-10-28 Lpath, Inc. Prevention and treatment of pain using antibodies to sphingosine-1-phosphate
US20110229471A1 (en) 2008-11-26 2011-09-22 Cedars-Sinai Medical Center Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease
US20110287088A1 (en) 2008-12-03 2011-11-24 Research Development Foundation Modulation of olfml-3 mediated angiogenesis
CN102573905A (zh) * 2008-12-05 2012-07-11 勒帕斯公司 利用抗脂类抗体晶体结构的抗体设计
US8401799B2 (en) * 2008-12-05 2013-03-19 Lpath, Inc. Antibody design using anti-lipid antibody crystal structures
EP2400981A4 (en) * 2009-02-26 2013-02-27 Lpath Inc DESGIN FOR HUMANIZED THROMBOZYTE ACTIVATION FACTOR ANTIBODIES BY ANTI-LIPID ANTIBODY TEMPLATES
WO2010121093A2 (en) * 2009-04-17 2010-10-21 Lpath, Inc. Humanized antibody compositions and methods for binding lysophosphatidic acid
US8859736B2 (en) 2010-02-19 2014-10-14 The Board Of Regents Of The University Of Oklahoma Monoclonal antibodies that inhibit the wnt signaling pathway and methods of production and use thereof
WO2011106723A2 (en) * 2010-02-26 2011-09-01 Lpath, Inc. Anti-paf antibodies
WO2012088265A1 (en) 2010-12-21 2012-06-28 Selexys Pharmaceuticals Corporation Anti-p-selectin antibodies and methods of their use and identification
PT3604339T (pt) 2011-01-14 2021-04-13 Univ California Anticorpos terapêuticos contra a proteína ror-1 e métodos para utilização dos mesmos
WO2012129520A1 (en) 2011-03-24 2012-09-27 Texas Tech University System Tcr mimic antibodies as vascular targeting tools
AU2012255143A1 (en) 2011-05-19 2014-02-20 The Regents Of The University Of Michigan Integrin alpha-2 binding agents and use thereof to inhibit cancer cell proliferation
CA2842971C (en) 2011-08-05 2019-11-12 Research Development Foundation Improved methods and compositions for modulation of olfml3 mediated angiogenesis
EP2897631A4 (en) 2012-08-31 2016-10-05 Univ Virginia Patent Found TARGET PEPTIDES FOR IMMUNOTHERAPY AND DIAGNOSTICS
WO2014039675A2 (en) 2012-09-05 2014-03-13 University Of Virginia Patent Foundation Target peptides for colorectal cancer therapy and diagnostics
AU2013334583B2 (en) 2012-10-24 2018-09-13 Research Development Foundation JAM-C antibodies and methods for treatment of cancer
HK1216153A1 (zh) 2012-12-13 2016-10-21 University Of Virginia Patent Foundation 用於卵巢癌治疗和诊断的靶向肽
BR112015024752A2 (pt) 2013-03-27 2017-07-18 Cedars Sinai Medical Center mitigação e reversão da fibrose e inflamação através da inibição da função de tl1a e vias de sinalização relacionadas
WO2015010108A1 (en) 2013-07-19 2015-01-22 Cedars-Sinai Medical Center Signature of tl1a (tnfsf15) signaling pathway
CA2921652A1 (en) 2013-08-21 2015-02-26 Manuel A. Riquelme Compositions and methods for targeting connexin hemichannels
MA45352A (fr) 2015-08-07 2018-06-13 Univ Birmingham Identification de glycopeptides associés à mhc de catégorie i comme cibles d'immunothérapie de cancer
JP7227007B2 (ja) 2015-12-02 2023-02-21 ストサイエンシス， インコーポレイテッド グリコシル化ｂｔｌａ（ｂ－及びｔ－リンパ球減弱因子）に特異的な抗体
EP3909983A1 (en) 2015-12-02 2021-11-17 STCube & Co. Inc. Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof
US10889637B2 (en) 2016-02-26 2021-01-12 The Board Of Regents Of The University Of Texas System Methods of treating an osteolytic tumor and spinal cord injury by administering connexin (Cx) 43 hemichannel-binding antibodies
JP7082945B2 (ja) 2016-03-17 2022-06-09 シーダーズ―シナイ メディカル センター Ｒｎａｓｅｔ２により炎症性腸疾患を診断する方法
CN109195991B (zh) 2016-03-29 2023-10-31 斯特库比股份有限公司 对糖基化pd-l1特异的双重功能抗体及其使用方法
CN109195990A (zh) 2016-03-30 2019-01-11 Musc研究发展基金会 通过靶向糖蛋白a重复优势蛋白(garp)治疗和诊断癌症以及单独或联合提供有效免疫疗法的方法
US11746152B2 (en) 2016-07-20 2023-09-05 Stcube, Inc. Methods of cancer treatment and therapy using a combination of antibodies that bind glycosylated PD-L1
WO2018081074A1 (en) 2016-10-26 2018-05-03 Cedars-Sinai Medical Center Neutralizing anti-tl1a monoclonal antibodies
JP7169298B2 (ja) 2017-05-12 2022-11-10 オーガスタ ユニバーシティ リサーチ インスティテュート，インコーポレーテッド ヒトアルファフェトタンパク質特異的ｔ細胞受容体およびその使用
KR102861670B1 (ko) 2017-05-31 2025-09-18 주식회사 에스티큐브앤컴퍼니 Btn1a1에 면역특이적으로 결합하는 항체 및 분자를 사용하여 암을 치료하는 방법
EP3630835A1 (en) 2017-05-31 2020-04-08 STCube & Co., Inc. Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof
JP2020522562A (ja) 2017-06-06 2020-07-30 ストキューブ アンド シーオー．， インコーポレイテッド Ｂｔｎ１ａ１又はｂｔｎ１ａ１リガンドに結合する抗体及び分子を用いて癌を治療する方法
WO2019025299A1 (en) 2017-07-31 2019-02-07 F. Hoffmann-La Roche Ag METHOD OF HUMANIZATION BASED ON THREE DIMENSIONAL STRUCTURE
DE112018005145T5 (de) 2017-09-15 2020-07-23 The Regents Of The University Of California Hemmung von aminoacylase 3 (aa3) bei der behandlung von krebs
KR20240017986A (ko) 2017-09-26 2024-02-08 더 리전트 오브 더 유니버시티 오브 캘리포니아 암 치료를 위한 조성물 및 방법
EP3737692A4 (en) 2018-01-09 2021-09-29 Elstar Therapeutics, Inc. CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES
WO2019178362A1 (en) 2018-03-14 2019-09-19 Elstar Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
EP3774916A2 (en) 2018-04-06 2021-02-17 Biolegend, Inc. Anti-tetraspanin 33 agents and compositions and methods for making and using the same
JP7332627B2 (ja) 2018-04-25 2023-08-23 プロメテウス バイオサイエンシーズ，インク． 最適化された抗ｔｌ１ａ抗体
CN112955465A (zh) 2018-07-03 2021-06-11 马伦戈治疗公司 抗tcr抗体分子及其用途
CN113365697B (zh) 2018-09-25 2024-07-19 百进生物科技公司 抗tlr9药剂和组合物及其制备方法和使用方法
EP3863671A4 (en) 2018-10-12 2022-07-20 Jumaa-Weinacht, Hassan MONOCLONAL ANTIBODY FOR THE TREATMENT OF ACUTE LYMPHOBLASTIC LEUKEMIA
EP3873514A4 (en) 2018-11-02 2022-11-02 Oklahoma Medical Research Foundation MONOCLONAL ANTIBODIES AGAINST ELTD1 AND USES THEREOF
CA3130628A1 (en) * 2019-02-21 2020-08-27 Marengo Therapeutics, Inc. Multifunctional molecules that bind to t cells and uses thereof to treat autoimmune disorders
CN114026122B (zh) 2019-02-21 2024-12-31 马伦戈治疗公司 结合t细胞相关癌细胞的多功能分子及其用途
WO2020172605A1 (en) 2019-02-21 2020-08-27 Elstar Therapeutics, Inc. Antibody molecules that bind to nkp30 and uses thereof
CN114127113A (zh) * 2019-02-21 2022-03-01 马伦戈治疗公司 与钙网蛋白结合的多功能分子及其用途
CA3131014A1 (en) * 2019-02-21 2020-08-27 Andreas Loew Anti-tcr antibody molecules and uses thereof
JP2022549504A (ja) 2019-09-26 2022-11-25 エスティーキューブ アンド カンパニー グリコシル化ｃｔｌａ－４に対して特異的な抗体およびその使用方法
CN114829404B (zh) 2019-10-09 2025-09-09 斯特库比公司 对糖基化的lag3特异的抗体及其使用方法
IL292419A (en) 2019-10-24 2022-06-01 Prometheus Biosciences Inc Humanized antibodies to tnf-like ligand 1a (tl1a) and uses thereof
EP4084823A4 (en) 2020-01-03 2024-05-15 Marengo Therapeutics, Inc. ANTI-TCR ANTIBODY MOLECULES AND THEIR USES
EP4084821A4 (en) 2020-01-03 2024-04-24 Marengo Therapeutics, Inc. Multifunctional molecules that bind to cd33 and uses thereof
CN115427447B (zh) 2020-01-17 2025-02-18 百进生物科技公司 抗tlr7药剂和组合物以及制备和使用其的方法
US20230106973A1 (en) 2020-02-17 2023-04-06 Board Of Regents, The University Of Texas System Methods for expansion of tumor infiltrating lymphocytes and use thereof
KR20230028242A (ko) 2020-04-24 2023-02-28 마렝고 테라퓨틱스, 인크. T 세포 관련 암 세포에 결합하는 다중기능성 분자 및 그것의 용도
WO2022047046A1 (en) 2020-08-26 2022-03-03 Marengo Therapeutics, Inc. Methods of detecting trbc1 or trbc2
CN116249718A (zh) 2020-08-26 2023-06-09 马伦戈治疗公司 结合至钙网蛋白的多功能性分子及其用途
WO2022093640A1 (en) 2020-10-30 2022-05-05 BioLegend, Inc. Anti-nkg2c agents and compositions and methods for making and using the same
WO2022093641A1 (en) 2020-10-30 2022-05-05 BioLegend, Inc. Anti-nkg2a agents and compositions and methods for making and using the same
US20240002541A1 (en) 2020-12-01 2024-01-04 The Johns Hopkins University Methods and materials for treating t cell cancers
WO2022216993A2 (en) 2021-04-08 2022-10-13 Marengo Therapeutics, Inc. Multifuntional molecules binding to tcr and uses thereof
EP4558523A1 (en) 2022-07-19 2025-05-28 Biolegend, Inc. Anti-cd157 antibodies, antigen-binding fragments thereof and compositions and methods for making and using the same
CN119968395A (zh) 2022-08-18 2025-05-09 百进生物科技公司 抗axl抗体、其抗原结合片段及其制备和使用方法
CN121152803A (zh) 2023-05-25 2025-12-16 百进公司 Ceacam6结合抗体和其抗原结合片段
WO2025036848A1 (en) 2023-08-11 2025-02-20 Wuxi Biologics (Shanghai) Co., Ltd. Anti-muc16 antibodies and uses thereof
WO2025072313A1 (en) 2023-09-27 2025-04-03 BioLegend, Inc. Anti-gpc4 antibodies
AR134368A1 (es) 2023-11-17 2026-01-07 Wuxi Biologics Ireland Ltd Anticuerpos anti-muc16 y usos de los mismos
WO2025247325A1 (en) * 2024-05-30 2025-12-04 Hanx Biopharmaceuticals, (Wuhan) Ltd. Antibody-drug conjugates targeting trbv12 and uses thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA811368B (en) * 1980-03-24 1982-04-28 Genentech Inc Bacterial polypedtide expression employing tryptophan promoter-operator
SU1404512A1 (ru) * 1983-01-27 1988-06-23 Институт биологической физики АН СССР Способ получени динуклеотидов
GB8607679D0 (en) * 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5426029A (en) * 1986-03-31 1995-06-20 T Cell Diagnostics, Inc. Therapeutic and diagnostic methods using leukocyte surface antigens
WO1989007142A1 (en) * 1988-02-05 1989-08-10 Morrison Sherie L Domain-modified constant region antibodies
ES2059719T3 (es) * 1988-02-12 1994-11-16 British Tech Group Mejoras relativas a anticuerpos.
US5766947A (en) * 1988-12-14 1998-06-16 Astra Ab Monoclonal antibodies reactive with an epitope of a Vβ3.1 variable region of a T cell receptor
US5223426A (en) * 1988-12-15 1993-06-29 T Cell Sciences, Inc. Monoclonal antibodies reactive with defined regions of the t-cell antigen receptor
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
CA2018248A1 (en) * 1989-06-07 1990-12-07 Clyde W. Shearman Monoclonal antibodies against the human alpha/beta t-cell receptor, their production and use
DE69031919T3 (de) * 1989-07-19 2005-01-27 Connetics Corp., Palo Alto T-zell-rezeptor-peptide als heilmittel für autoimmune und bösartige krankheiten
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5067193A (en) * 1990-07-26 1991-11-26 Container Graphics Corporation Rotary printing plate washing apparatus
US5445940A (en) * 1991-08-28 1995-08-29 Brigham & Women's Hospital Methods and compositions for detecting and treating a subset of human patients having an autoimmune disease

Also Published As

Publication number Publication date
AU1033395A (en) 1995-06-27
IL111926A (en) 2002-07-25
JPH09509307A (ja) 1997-09-22
CZ162896A3 (en) 1997-01-15
NO962346L (no) 1996-08-06
FI962377L (fi) 1996-07-30
WO1995016038A2 (en) 1995-06-15
PL314908A1 (en) 1996-09-30
BR9408278A (pt) 1996-12-17
CZ287298B6 (cs) 2000-10-11
NZ276170A (en) 1998-05-27
US5861155A (en) 1999-01-19
EP0737250A1 (en) 1996-10-16
EE03271B1 (et) 2000-06-15
KR100239607B1 (ko) 2000-01-15
LV11631A (lv) 1996-12-20
SK73596A3 (en) 1997-05-07
SG48420A1 (en) 1998-04-17
ZA949341B (en) 1996-05-24
FI962377A0 (fi) 1996-06-07
HUT75553A (en) 1997-05-28
PL180157B1 (en) 2000-12-29
WO1995016038A3 (en) 1995-07-06
HU9601574D0 (en) 1996-07-29
CZ287347B6 (en) 2000-10-11
UA29494C2 (uk) 2000-11-15
KR100258902B1 (en) 2000-06-15
IL111926A0 (en) 1995-03-15
FI962377A7 (fi) 1996-07-30
KR960706560A (ko) 1996-12-09
CN1063792C (zh) 2001-03-28
GB9325182D0 (en) 1994-02-09
CA2178622A1 (en) 1995-06-15
CN1142855A (zh) 1997-02-12
LV11631B (en) 1997-04-20
RU2139934C1 (ru) 1999-10-20
AU699249B2 (en) 1998-11-26

Similar Documents

Publication Publication Date Title
NO962346D0 (no) Humaniserte antistoffer og anvendelser derav
DK0721469T3 (da) Anti-gp39-antistoffer og anvendelse deraf
NO921863L (no) Antistoffer og anvendelse derav
DK145493D0 (da) Antistof
NO955167D0 (no) Monoklonalt anti-
FI955798L (fi) Terapeuttiset vasta-ainefrangmentit
FI961285L (fi) CD40:n vasta-aineita
NO943763D0 (no) 4-arylamino-benzopyraner og beslektede forbindelser
BR9404967A (pt) Imunoensaio
DE69322847D1 (de) Monoklonaler Antikörper gegen menschliches Ceruloplasmin
FI945485L (fi) Monoklonaaliset vasta-aineet ja niiden käyttö
DE69427850D1 (de) Monoklonaler antikörper gegen mucoglykoprotein
PL311666A1 (en) P-selection antibodies and their application
DK251090D0 (da) Antistoffer og anvendelse deraf
DE69324928D1 (de) Monoklonaler antikörper
BR9303330A (pt) Fecho
ITMI931648A1 (it) Azaciclo e azabiciclo ammidi
CA72930S (fr) Bracelet
KR950021909U (ko) 휴대용 전화기의 소프트 케이스
NO934392D0 (no) Rullgardin og beslag for rullgardin
GB9315249D0 (en) Antigen-binding proteins
GB9210944D0 (en) Monoclonal antibodies and their use
GB9204514D0 (en) Monoclonal antibodies and their use
GB9210930D0 (en) Monoclonal antibodies and their use
GB9210929D0 (en) Monoclonal antibodies and their use

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application